1.
Menter A, Blauvelt A, Strober B, Colombo M, Kisa R, Kundu S, Banerjee S, Leonardi C. Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. J of Skin [Internet]. 2020Oct.27 [cited 2022Aug.18];4(6):s72. Available from: https://jofskin.org/index.php/skin/article/view/1105